Cargando…
Prediction of therapeutic value of new drugs approved by health Canada from 2011−2020: A cross-sectional study
OBJECTIVES: To examine whether a combination of three characteristics of new drugs – review type, outcome of premarket trials (surrogate or clinical) and first-in-class is associated with significant therapeutic value. DESIGN: Cross-sectional analysis of new drugs approved by Health Canada from Janu...
Autor principal: | Lexchin, Joel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225954/ https://www.ncbi.nlm.nih.gov/pubmed/37255526 http://dx.doi.org/10.1177/20542704231166620 |
Ejemplares similares
-
Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study
por: Lexchin, Joel
Publicado: (2022) -
How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009
por: Lexchin, Joel
Publicado: (2014) -
Time to market for drugs approved in Canada between 2014 and 2018: an observational study
por: Lexchin, Joel
Publicado: (2021) -
How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2016) -
Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study
por: Lexchin, Joel
Publicado: (2018)